Accéder au contenu
Merck
  • Optimized Heart Sampling and Systematic Evaluation of Cardiac Therapies in Mouse Models of Ischemic Injury: Assessment of Cardiac Remodeling and Semi-Automated Quantification of Myocardial Infarct Size.

Optimized Heart Sampling and Systematic Evaluation of Cardiac Therapies in Mouse Models of Ischemic Injury: Assessment of Cardiac Remodeling and Semi-Automated Quantification of Myocardial Infarct Size.

Current protocols in mouse biology (2015-12-03)
Mariana Valente, Ana Araújo, Tiago Esteves, Tiago L Laundos, Ana G Freire, Pedro Quelhas, Perpétua Pinto-do-Ó, Diana S Nascimento
RÉSUMÉ

Cardiac therapies are commonly tested preclinically in small-animal models of myocardial infarction. Following functional evaluation, post-mortem histological analysis is essential to assess morphological and molecular alterations underlying the effectiveness of treatment. However, non-methodical and inadequate sampling of the left ventricle often leads to misinterpretations and variability, making direct study comparisons unreliable. Protocols are provided for representative sampling of the ischemic mouse heart followed by morphometric analysis of the left ventricle. Extending the use of this sampling to other types of in situ analysis is also illustrated through the assessment of neovascularization and cellular engraftment in a cell-based therapy setting. This is of interest to the general cardiovascular research community as it details methods for standardization and simplification of histo-morphometric evaluation of emergent heart therapies. © 2015 by John Wiley & Sons, Inc.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-noyau, clone 3E1.3, clone 3E1.3, Chemicon®, from mouse
Sigma-Aldrich
Mouse IgG1 Negative Control, clone Ci4, Mouse IgG1 Negative Control Monoclonal Antibody validated for use in Flow Cytometry & Immunofluorescence.